London, 13 October 2014 – TechNavio, a global tech-focused research firm has announced the publication of its market research report on the Global Influenza Market 2014-2018.
Influenza is a contagious respiratory disease caused by influenza viruses. Elderly people, young children and people with medical conditions like liver disorders, blood disorders, kidney disorders, chronic lung disease, asthma and neurodevelopmental and neurological conditions are at higher risk of getting infected. The Global Influenza Market is growing at a moderate rate and is expected to post a CAGR of 8.10 percent during the period 2013-2018.
About the Report
The latest report by TechNavio focuses on the emergence of trivalent and quadrivalent vaccines for active immunization against three or four strains of influenza virus, respectively.
“Annually, the WHO analyzes and recommends influenza virus strains to be incorporated in flu vaccines for the upcoming flu seasons. In 2012, the WHO recommended an additional strain B to be used in quadrivalent vaccines along with the recommended strains for trivalent vaccines and in February 2012, the FDA approved FluMist Quadrivalent, the first quadrivalent vaccine, as Fluenz Tetra, in the US,” says Faisal Ghaus, Vice President of TechNavio.
Key Information Covered in the Report:
Market segmentation, size and forecast through 2018
Market Growth Drivers:
- Increase in Awareness Regarding Influenza
- For a full detailed list, view our report.
Market Challenges:
- Antigenic Drift of Influenza Viruses
- For a full detailed list, view our report.
Market Trends:
- Emergence of Quadrivalent Vaccines for H1N1 Influenza
- For a full detailed list, view our report.
Key Vendors:
- AstraZeneca plc
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Novartis AG
- Sanofi Pasteur SA
Other Prominent Vendors:
- Abbott
- Baxter International
- bioCSL
- Crucell
https://www.technavio.com/%3Cp%3E%3Ca%20href%3D%22http%3A//www.technavio….
